
Exploring Recent Developments in the Treatment of Prostate Cancer
Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
1:56-4:02 - Importance of trial design in therapy selection
4:02-8:09 - Benefits of cooperative trials and comparison of trial end points
8:09-12:10 - Applicability of trial inclusion criteria in daily practice
12:10-13:17 - Moving away from ADT monotherapy as a comparator and applicability of subset analysis
13:17-16:08 - Evaluating the relevance of a clinical trial
16:08-18:59 - Translating statistical significance, biomarker analysis, and subgroup analysis to the clinic
18:59-22:34 - Use of rPFS in informing clinical decisions
22:34-26:56 - Evaluation of patients with conventional imaging and PSMA PET
26:56-31:14 - Importance of quality of life data in clinical trials
31:14-34:34 - Importance of trial design in evaluating a therapy
34:34-37:22 - Patient selection for triplet therapy
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

















